Global cancer rates are soaring and whereas treatments increasingly extend life, side effects can severely limit and delay treatment. Effective supportive care ensures a patient’s treatment remains on track.
NXP001 will enable wider patient access to an under-utilised product within the growing oncology supportive care market. Despite global approval as a first-line treatment alongside chemotherapy, patient access remains limited to the currently marketed product, as formulation complexity and IP restrict generic access.
- A cocrystal-approach will enable a bioequivalent product without infringing existing IP.
- Demonstration of oral bioequivalence for NXP001 will enable global generic approval and wider patient benefit/access.
- License partners will have a significant opportunity to increase global market access beyond what is currently possible.